considerations evaluation starting glp-1 GLP-1's: What They Are and What the Research Says Stopping GLP-1s: Weight Regain and

Program is life-changing for some, frustrating for others GLP-1s have soared in popularity in recent years, and theyve spurred dramatic weight loss in many patients

The state is grappling with rising obesity rates, an issue that impacts millions of lives and contributes to a host of complex health challenges

March 5, 2026: FDA Issues Warning Letter to Novo Nordisk About Reporting Adverse Events for its GLP-1s The FDAs Center for Drug Evaluation and Research (CDER) has issued a warning letter to Novo Nordisk, Ozempics maker

AHK-Cu significantly stimulates vascular endothelial growth factor (VEGF), a key driver of angiogenesis, or the formation of new capillaries that deliver oxygen and nutrients to dermal tissue

While the potential for Ozempic face exists, its important to weigh this potential against the proven benefits of the drug in managing type 2 diabetes

Abstract Tirzepatide is the first dual GIP/GLP-1 receptor co-agonist approved for the treatment of type 2 diabetes in the USA, Europe, and the UAE